<DOC>
	<DOCNO>NCT01389063</DOCNO>
	<brief_summary>HIV infect patient treat abacavir might high risk occurrence cardiovascular event . At time write protocol underlie mechanism yet elucidate , however study find impaired endothelial function elevate marker chronic inflammation patient , suggest high lever chronic inflammation . Recently maraviroc ( Celsentri® ) , CCR5-receptor antagonist , become available treatment patient infect HIV-1 . Improvement endothelial function may potential beneficial side effect treatment maraviroc , due potential reduction immune activation chronic inflammation result block CCR5-coreceptor . Moreover , treatment intensification HAART maraviroc patient suppress plasma HIV_RNA may decrease plasma HIVRNA cut-off 50 copies/ml well . The investigator hypothesize maraviroc intensification therapy patient abacavir-containing regimen improve endothelial function . The objective study : First , assess effect addition maraviroc abacavir-containing regimen endothelial function ; second , assess effect intervention marker immune activation chronic inflammation , plasma HIV-RNA 50 copies/ml .</brief_summary>
	<brief_title>Maraviroc Abacavir STudy - Effect Endothelial Recovery</brief_title>
	<detailed_description>The MASTER study phase IV , randomize , open label , cross-over , intervention study . Study subject stable abacavir-containing regimen randomize two arm . In arm A maraviroc add regimen baseline , study subject arm B continue abacavir-containing regimen . After 8 week , cross-over study arm perform . Subjects arm A stop maraviroc , subject arm B maraviroc add regimen ( 8 week ) . The total duration study 16 week .</detailed_description>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Age &gt; 18 year HIV1 infection Treatment antiretroviral regimen contain abacavir least previous 3 month Undetectable plasma HIV RNA ( 50 cp/ml ) least 6 month ( one 'blip ' allow , define detectable plasma HIVRNA level 50 400 copies/ml , precede follow undetectable ( &lt; 50 copies/ml ) plasma HIVRNA measurement ) CD4+ cell count &gt; 200 cells/μL Signed informed consent Pregnancy Breastfeeding Allergy peanuts soya Hypersensitivity maraviroc Treatment underlying malignancy Acute infection precede 30 day Renal insufficiency require hemodialysis Acute decompensated chronic hepatitis Modification antiretroviral regimen previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>endothelial function</keyword>
	<keyword>CCR5 receptor</keyword>
	<keyword>Maraviroc</keyword>
	<keyword>Abacavir</keyword>
	<keyword>Flow Mediated Dilatation</keyword>
	<keyword>EndoPAT</keyword>
</DOC>